Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Adaptimmune
Biotech
Adaptimmune's cell therapy hits key goal in pivotal sarcoma test
Adaptimmune is prepping for another FDA submission after its cell therapy was tied to a 42% response rate in a phase 2 sarcoma trial.
Gabrielle Masson
Nov 13, 2024 2:57pm
Galapagos selects Adaptimmune cell therapy in $665M collab
May 31, 2024 9:40am
Genentech axes $3B Adaptimmune cell therapy deal
Apr 12, 2024 11:22am
Trio of biotechs toss programs to discard pile
Nov 9, 2023 11:23am
FDA's Peter Marks doesn't plan to retire soon—Chutes & Ladders
Aug 4, 2023 9:30am
GSK pays out £30M to Adaptimmune as cell therapy work ends
Apr 11, 2023 11:47am
